Contribution of capecitabine for therapy of patients with gastroesophageal cancer: an update of recent phase III results | Zendy

Putao Cen | Zendy; Eric D. Tetzlaff | Zendy; Jaffer A. Ajani | Zendy

Open Access

Contribution of capecitabine for therapy of patients with gastroesophageal cancer: an update of recent phase III results

Author(s) -

Putao Cen,

Eric D. Tetzlaff,

Jaffer A. Ajani

Publication year - 2008

Publication title -

therapeutics and clinical risk management

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.719

H-Index - 55

eISSN - 1178-203X

pISSN - 1176-6336

DOI - 10.2147/tcrm.s1446

Subject(s) - capecitabine , medicine , clinical trial , cancer , oncology , fluorouracil , phases of clinical research , colorectal cancer

Capecitabine, an orally administered fluoropyrimidines, is widely used in the treatment of multiple malignancies. It has been extensively evaluated in patients with gastroesophageal carcinoma. Since recent reviews have discussed phase I/II trials (Cancer 107:221-231, 2006; Drugs 67:601-610, 2007), we focus on the impact of the results of the most current phase III trials using capectiabine in the treatment of advanced gastroesophageal cancers, primarily in the first-line setting.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research